Fixed Dose Rate versus Standard Dose Rate Infusion of Gemcitabine and Cisplatin in Advanced Stage Non-Small Cell Lung Cancer


Background: Comparing the efficacy and safety of gemcitabine at a fixed-dose rate (FDR) infusion (10 mg/m2/min) with the standard dose rate infusion in patients with locally advanced and metastatic non-small squamous cell carcinoma (NSCLC). Methods: The study randomized 60 patients with confirmed diagnosis of NSCLC to receive gemcitabine at a dose of 1000 mg/m2 on days 1 and 8 given as a 30-min infusion (Arm A) or at a rate of 10 mg/m2/min (Arm B). Cisplatin 75 mg/m2 was administered intravenously on day 2 in both arms. Results: No difference in overall response rate (46.6% versus 43.3%). Median time to progression for Arm A was 7 months (95% CI, 6.207 - 7.793 months), versus 6 months for Arm B (95% CI, 4.990 - 7.010 months). Median survival time was comparable [12 months (95% CI, 8.588 - 15.412 months) versus 11 months (95% CI, 9.066 - 12.934 months)] respectively. Two-year survival (18% versus 11%, p = 0.38) was detected. No treatment related deaths occurred. Main hematological toxicities were grade I and II neutropenia, in 36.7% and 53.3% respectively (p = 0.044). Grade III anemia was observed in 10% and 6.7% in both arms respectively (p = 0.024). Grade I and II nausea and vomiting was observed in 50% and 46.7%. Conclusions: FDR gemcitabine in combination with cisplatin had equivalent efficacy and more severe hematologic toxicities compared to the standard 30-min gemcitabine infusion with cisplatin in patients with advanced NSCLC.

Share and Cite:

Salem, D. , Ibrahim, D. , Ezzat, A. and Adel, A. (2015) Fixed Dose Rate versus Standard Dose Rate Infusion of Gemcitabine and Cisplatin in Advanced Stage Non-Small Cell Lung Cancer. Journal of Cancer Therapy, 6, 45-52. doi: 10.4236/jct.2015.61007.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Siegel, R.L., Naishadham, D. and Jamal, A. (2012) Cancer Statistics. CA: A Cancer Journal for Clinicians, 62, 10-29.
[2] Ferlay, J., Shin, H.R., Bary, F., et al. (2010) GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10. International Agency for Research on Cancer, Lyon.
[3] Greene, F.L., Page, D.L., Fleming, I.D., Firtz, A., Balch, D.G. and Haller, M.M. (2002) AJCC Cancer Staging Manual. 6th Edition, Springer-Verlag, Berlin/Heidelberg/New York/London/Paris/Tokyo/Hong Kong, 435.
[4] Arriagada, R., Auperin, A., Burdett, S., Higgins, J.P., Johnson, D.H., Le Chevalier, T., Le Pechoux, C., Pamar, M.K., Pignon, P.J., Souhami, R.L., Stephens, R.J., Stewart, L.A., Tierney, J.F., Tribodet, H. and van Meerbeeck, J., On Behalf of the NSCLC Meta-Analyses Collaborative Group (2010) Adjuvant Chemotherapy with or witout Postoperative Radiotherapy in Operable Non-Small-Cell Lung Cancer: Two Meta-Analyses of Individual Patient Data. Lancet, 375, 1267-1277.
[5] Scagliotti, G.V., De Marinis, F., Rinaldi, M., Crino, L., Gridelli, C., Ricci, S., Matano, E., Boni, C., Marangolo, M., Failla, G., Altavilla, G., Adamo, V., Ceribelli, A., Clerici, M., Di Costanzo, F., Frontini, L. and Tona, M. (2002) Phase III Randomized Trial Comparing Three Platinum-Based Doublets in Advanced Non-Small Cell Lung M. Cancer Italian Lung Cancer Project. Journal of Clinical Oncology, 20, 4285-4291.
[6] Pastor-Anglada, M., Molina-Arcas, M., Casado, F.J., Bellosillo, B., Colomer, D. and Gil, J. (2004) Nucleoside Transporters in Chronic Lymphocytic Leukemia. Leukemia, 18, 385-393.
[7] Abratt, R.P., Bezwoda, W.R., Falkson, G., Goedhals, L., Hacking, D. and Rugg, T.A. (1994) Efficacy and Safety Profile of Gemcitabine in Non-Small-Cell Lung Cancer: A Phase II Study. Journal of Clinical Oncology, 12, 1535-1540.
[8] Tempero, M., Plunkett, W., Ruiz Van Haperen, V., Hainsworth, J., Lenzi, R. and Abbruzzese, J. (2003) Randomized Phase II Comparison of Dose-Intense Gemcitabine: Thirty-Minute Infusion and Fixed Dose Rate Infusion in Patients with Pancreatic Adenocarcinoma. Journal of Clinical Oncology, 21, 3402-3408.
[9] Ceribelli, A., Gridelli, C., De Marinis, F., Fabi, A., Gamucci, T., Cortesi, E., Barduagni, M., Antimi, M., Maione, P., Migliorino, M.R., Giannarelli, D. and Cognetti, F. (2003) Prolonged Gemcitabine Infusion in Advanced Non-Small Cell Lung Carcinoma: A Randomized Phase II Study of Two Different Schedules in Combination with Cisplatin. Cancer, 98, 337-343.
[10] Cappuzzo, F., Novello, S., De Marinis, F., Selvaggi, G., Scagliotti, G.V., Barbieri F., Maur, M., Papi, M., Bartolini, S., Marini, L. and Crino, L. (2006) A Randomized Phase II Trial Evaluating Standard (50 mg/min) versus Low (10 mg/min) Infusion Duration of Gemcitabine as First-Line Treatment in Advanced Non-Small-Cell Lung Cancer Patients Who Are Not Eligible for Platinum-Based Chemotherapy. Lung Cancer, 52, 319-325.
[11] Soo, R.A., Wang, L.Z., Tham, L.S., Yong, W.P., Boyer, M., Lim, H.L., Lee, H.S., Millward, M., Liang, S., Beale, P., Lee, S.C. and Goh, B.C. (2006) A Multicenter Randomized Phase II Study of Carboplatin in Combination to Gemcitabine at Standard Rate or Fixed Dose Rate Infusion in Patients with Advanced Stage Non-Small-Cell Lung Cancer. Annals of Oncology, 17, 128-133.
[12] Gridelli, C., Gallo, C., Ceribelli, A., Gebbia, V., Gamucci, T., Ciardiello, F., Carozza, F., Favaretto, A., Daniele, B., Galetta, D., Barbera, S., Rosette, F., Rossi, A., Maione, P., Cognetti, F., Testa, A., Di Maio, M., Morabito, A., Perrone, F. and GECO Investigators (2007) Factorial Phase III Randomized Trial of Rofecoxib and Prolonged Constant Infusion of Gemcitabine in Advanced Non-Small-Cell Lung Cancer: The GEmcitabine-COxib in NSCLC (GECO) Study. Lancet Oncology, 8, 500-512.
[13] Wang, L.R., Huang, M.Z., Zhang, G.B., Xu, N. and Wu, X.H. (2007) Phase II Study of Gemcitabine and Carboplatin in Patients with Advanced Non-Small-Cell Lung Cancer. Cancer Chemotherapy and Pharmacology, 60, 601-607.
[14] Pereira, J.R., Fein, L., Del Giglio, A., Blajman, C.R., Richardet, E., Schwartsmann, G., Orlando, M., Hall, B.J., West, T.M. and van Kooten, M. (2007) Gemcitabine Administered as a Short Infusion versus a Fixed Dose Rate in Combination with Cisplatin for the Treatment of Patients with Advanced Non-Small Cell Lung Cancer. Lung Cancer, 58, 80-87.
[15] Therasse, P., Arbuck, S.G., Eisenhauer, E.A., Wanders, J., Kaplan, R.S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A.T., Christian, M.C. and Gwyther, S.G. (2000) New Guidelines to Evaluate the Response to Treatment in Solid Tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute, 92, 205-216.
[16] (2003) Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS. http://cte
[17] Qui, M.T., Ding, X.X., Hu, J.W., Tian, H.Y., Yin, R. and Xu, L. (2012) Fixed-Dose Rate Infusion and Standard Rate Infusion of Gemcitabine in Patients with Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis of Six Trials. Cancer Chemotherapy and Pharmacology, 70, 861-873.
[18] Xu, N., Shen, P., Zhang, X.C., Yu, L.F., Bao, H.Y., Shi, G.M., Huanq, S., Chen, J., Mou, H.B. and Fang, W.J. (2007) Phase II Trial of a 2-h Infusion of Gemcitabine plus Carboplatin as First-Line Chemotherapy for Advanced Non-Small-Cell Lung Cancer. Cancer Chemotherapy and Pharmacology, 59, 1-7.
[19] Tibaldi, C., Bernardini, I., Chella, A., Russo, F., Toma, G., Tempestini, F., Malventi, M., Vasile, E, Ambrosino, N. and Falcone, A. (2006) Prolonged Gemcitabine Infusion in Advanced Non-Small-Cell Lung Cancer with Stable Disease after Gemcitabine 30-Min Infusion. Lung Cancer, 51, 217-223.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.